Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has issued an announcement.
Telix Pharmaceuticals has completed the acquisition of assets from ImaginAb, Inc., including a pipeline of next-generation therapeutic candidates and a novel biologics technology platform. This acquisition is expected to enhance Telix’s innovation capabilities and expand its therapeutics pipeline, targeting validated and novel cancer targets. With the integration of a Los Angeles research facility and ImaginAb’s team, Telix aims to advance its position in precision medicine and theranostic radiopharmaceuticals, potentially impacting its operations, industry standing, and stakeholder interests.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Canada, Europe, and Japan. The company develops a portfolio of clinical and commercial stage products targeting unmet medical needs in oncology and rare diseases.
YTD Price Performance: 27.45%
Average Trading Volume: 4,346
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.91B
Learn more about TLX stock on TipRanks’ Stock Analysis page.
